Cardiff Oncology Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
Cardiff Oncology Stock Forecast and Price Target
The average price target for Cardiff Oncology's stock set by recognized analysts recently is $8.68, which would result in a potential upside of approximately 93.75% if it reached this mark. The estimation is based on a high estimate of $14.00 and a low estimate of $7.00. If you're interested in investing in this company, why not also look at its competitors to see how they are doing?
93.75% Upside
Cardiff Oncology Fair Value Forecast for 2023 - 2025 - 2030
Cardiff Oncology's Price has seen impressive growth In the last two years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $4.81 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DGX Stock Forecast | Quest Diagnostics | Outperform |
10
|
$136.34 | Buy/Sell | $141.17 | 6.35% |
| EXAS Stock Forecast | Exact Sciences | Buy |
8
|
$60.54 | Buy/Sell | $90.32 | 47.36% |
| GH Stock Forecast | Guardant Health | Buy |
6
|
$18.58 | Buy/Sell | $43.00 | 136.81% |
| NEO Stock Forecast | NeoGenomics | Outperform |
8
|
$14.72 | Buy/Sell | $20.09 | 29.08% |
| VCYT Stock Forecast | Veracyte | Outperform |
11
|
$20.19 | Buy/Sell | $32.17 | 60.97% |
Cardiff Oncology Revenue Forecast for 2023 - 2025 - 2030
Cardiff Oncology's Revenue has seen impressive growth In the last three years, rising from $370.00k to $490.00k – a growth of 32.43%. The next year, 4 experts forecast that Cardiff Oncology's Revenue will decrease by 69.39%, reaching $150.00k. For the next seven years, the forecast is for Revenue to grow by 25027.13%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PSNL Stock Forecast | Personalis | Outperform |
6
|
$1.60 | Buy/Sell | $4.45 | 150.00% |
| AXDX Stock Forecast | Accelerate Diagnostics | Buy |
8
|
$0.94 | Buy/Sell | $5.00 | -100.00% |
| HTGM.Q Stock Forecast | HTG Molecular Diagnostics | - |
6
|
$0.00 | Buy/Sell | $6.00 | 0.00% |
.jpg)
Cardiff Oncology EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Cardiff Oncology's EBITDA has seen an increase, rising from $-18.62M to $-45.01M. This represents a growth of 141.73%. According to 0 prominent analysts, Cardiff Oncology's EBITDA will fall by 24.90% in the next year, reaching $-33.80M. By 2030, professionals believe that Cardiff Oncology's EBITDA will decrease by 20.42%, reaching $-35.82M – a concerning trend for the company.
Cardiff Oncology EBIT Forecast for 2023 - 2025 - 2030
Cardiff Oncology's EBIT has seen growth In the last three years, going from $-19.09M to $-45.41M – a gain of 137.87% In the next year, analysts believe that EBIT will reach $-61.10M – an increase of 34.55%. In 2030, professionals predict that Cardiff Oncology's EBIT will decrease by 2537.79%, to $1.11B.
Cardiff Oncology EPS Price Prediction Forecast for 2023 - 2025 - 2030
Cardiff Oncology's EPS has seen impressive growth In the last two years, rising from $-0.89 to $0.00 – a growth of 100.00%. In the next year, analysts believe that EPS will reach $-1.25 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
.jpg)